Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Jefferies has reiterated its 'buy' rating on GSK PLC (LSE:GSK, NYSE:GSK), the pharmaceutical company, with a 2,500p price target after US regulators approved its hepatitis B treatment, Hibsago. The target represents a potential upside of 34% from the 1,868.5p closing price used in the broker's 21 October research note.

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B (CHB) virus infection in combination with nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI) therapy in adult patients without cirrhosis, receiving NrtI therapy for at least 6 months, who have suppressed HBV deoxyribonucleic acid (DNA), and with hepatitis B virus (HBV) surface antigen (HBsAg).

US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment

GSK's newer drugs, expanding indications and promising pipeline could drive long-term growth, with sales expected to exceed 40 billion pounds by 2031.

Jefferies rates GSK PLC (LSE:GSK, NYSE:GSK), the FTSE 100 pharmaceutical company, 'buy' with a 2,500p price target, implying 34% upside from Friday's close of 1,862.50p, after global trial results for its experimental cancer drug ris-rez showed a 61% tumour response rate. The EMBOLD study in extensive-stage small-cell lung cancer showed an objective response rate of 61% among patients receiving 8mg/kg, with 11 of 18 responding, compared with 32%, or 7 of 22 patients, at 6mg/kg.

GSK PLC (LSE:GSK, NYSE:GSK) said its experimental lung cancer treatment risvutatug rezetecan produced a 61% confirmed response rate at the higher dose tested in an early-stage global trial of patients with relapsed extensive-stage small cell lung cancer. The FTSE 100 pharmaceutical group said 11 of 18 evaluable patients receiving an 8 milligram per kilogram dose responded to treatment, compared with seven of 22 patients, or 32%, receiving the lower 6 milligram dose.

GSK (NYSE: GSK - Get Free Report) and United-Guardian (NASDAQ: UG - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability. Analyst Recommendations This is a breakdown of recent ratings and